Welcome to Double Bond Pharmaceutical website. Our mission is to provide patients with more efficient and safer products in areas where their needs are not met. To this end, Double Bond Pharmaceutical’s scientific team has been working hard to overcome the drawbacks of widely available treatment options that have already proven their effectiveness. We focus on the redevelopment of known drugs by changing the route of administration to develop new formulations designed to reduce side effects and improve efficacy. Our vision is that medicines work best when they are delivered to the right place at the right time.
Welcome to Double Bond Pharmaceutical website. Our mission is to provide patients with more efficient and safer products in areas where their needs are not met. To this end, Double Bond Pharmaceutical’s scientific team has been working hard to overcome the drawbacks of widely available treatment options that have already proven their effectiveness. We focus on the redevelopment of known drugs by changing the route of administration to develop new formulations designed to reduce side effects and improve efficacy. Our vision is that medicines work best when they are delivered to the right place at the right time.
Our Products
At Double Bond Pharmaceutical, our areas of expertise are brain cancer, liver cancer and pneumonia. We have developed ways to treat these diseases much more effectively with our drug delivery system.
At Double Bond Pharmaceutical, our areas of expertise are brain cancer, liver cancer and pneumonia. We have developed ways to treat these diseases much more effectively with our drug delivery system.
SI-053 is a temozolomide gel that is administered locally into the cavity created after resection of glioblastoma.
SI-053 is a temozolomide gel that is administered locally into the cavity created after resection of glioblastoma.
BeloGal® is a drug delivery system based on biomimetic encapsulation of the active pharmaceutical ingredient with a polymer- and biology-free excipient that radically increased the therapeutic effect while protecting the remaining healthy tissues from toxic effects.
We also utilize an innovative hydrogel to allow the delivery of active pharmaceutical ingredients to the resection cavity in the brain.
BeloGal® is a drug delivery system based on biomimetic encapsulation of the active pharmaceutical ingredient with a polymer- and biology-free excipient that radically increased the therapeutic effect while protecting the remaining healthy tissues from toxic effects.
We also utilize an innovative hydrogel
to allow the delivery of active pharmaceutical ingredients to the resection cavity in the brain.
SA-033 is a novel treatment of cancers in liver. It is the first drug candidate that our company has developed using our first-in-class technology BeloGal®, which enables direct targeting of a drug to the selected organ, which in the case of SA-033 means that doxorubicin is targeted directly to the liver.
SA-033 is a novel treatment of cancers in liver. It is the first drug candidate that our company DBP has developed using our first-in-class technology BeloGal®, which enables direct targeting of a drug to the selected organ, which in the case of SA-033 means that doxorubicin is targeted directly to the liver.
Belopenem is based on BeloGal® and selectively directs the broad spectrum antibiotic meropenem to the infected lungs of pneumonia patients.
Belopenem is based on BeloGal® and selectively directs the broad spectrum antibiotic meropenem to the infected lungs of pneumonia patients.
Why SI-053 Is
a Game-changer?
In 2022, 320,000 adults were diagnosed with brain and CNS tumors, and 250,000 died.
(Global Cancer Observatory)
In 2022, 320,000 adults were diagnosed with brain and CNS tumors, and 250,000 died (Global Cancer Observatory).
Surgery is critical for eliminating the bulk of the tumor, offering the best chance to prolong survival and alleviate symptoms.
However, malignant brain tumors like glioblastoma infiltrate surrounding healthy tissue. Glioblastoma is characterized by its highly aggressive nature and fast growth. This makes it very hard to treat, leading to recurrence and death.
The Stupp protocol, the standard of care for glioblastoma, includes maximum safe resection, radiotherapy (RT) and systemic temozolomide (TMZ). This protocol extends survival by 10 months
on average.
The Stupp protocol, the standard of care for glioblastoma, includes maximum safe resection, radiotherapy (RT) and systemic temozolomide (TMZ). This protocol extends survival by 10 months on average.
However, oral temozolomide causes systemic toxicity and poor drug delivery to brain cancer due to the blood-brain barrier. Many patients can’t complete chemotherapy due to side effects and disease progression, leaving high levels of residual microscopic disease and a high risk of recurrence.
Our analysis of 25 years of clinical studies involving 8713 patients with newly diagnosed glioblastoma revealed that adding systemic experimental treatment to the Stupp protocol only provided an additional 2.7 months of survival. Locally delivered experimental treatment resulted in an additional 2.9 months of survival. In contrast, Temodex, a prototype product of SI-053, extended survival by
5 months in addition to standard care, showing a 57% improvement in survival
compared to the control group.
Our analysis of 25 years of clinical studies involving 8713 patients with newly diagnosed glioblastoma revealed that adding systemic experimental treatment to the Stupp protocol only provided an additional 2.7 months of survival. Locally delivered experimental treatment resulted in an additional 2.9 months of survival. In contrast, Temodex, a prototype product of SI-053, extended survival by 5 months in addition to standard care, showing a 57% improvement in survival compared to the control group.
SI-053 allows direct delivery of temozolomide to the tumor, potentially prolonging survival, progression-free survival, and treatment-free intervals. To read more about SI-053/Temodex,
please go to Our Products page.
SI-053 allows direct delivery of temozolomide to the tumor, potentially prolonging survival, progression-free survival, and treatment-free intervals.
To read more about SI-053/Temodex,
please go to Our Products page.